IGFBP7 and TIMP2 as Biomarkers of Acute Kidney Injury

  • Research type

    Research Study

  • Full title

    Prospective Observational Cohort Study Investigating the Clinical Utility of IGFBP7 and TIMP2 as Biomarkers of Acute Kidney Injury in Critically Ill Patients

  • IRAS ID

    182994

  • Contact name

    Colin Bicknell

  • Contact email

    colin.bicknell@imperial.ac.uk

  • Sponsor organisation

    Joint Research Compliance Office

  • Duration of Study in the UK

    0 years, 6 months, 5 days

  • Research summary

    Acute Kidney Injury (AKI) is common in hospitalised patients and increases the risk of death but is treatable and early intervention is beneficial. International guidelines from Kidney Disease Improving Global Outcomes (KDIGO) currently define AKI according to a rise in a blood test marker (serum creatinine) or a reduction in urine output. Two recent multicentre studies have shown promise for two novel biomarkers of AKI: TIMP-2 and IGF-BP7. These biomarkers may allow earlier detection and intervention for AKI, with the expectation of improved outcomes. However the clinical utility of these biomarkers in real patient populations has not yet been established.

    This prospective observational cohort study aims to assess the value of these novel AKI biomarkers in predicting common but differing clinical situations to allow clinical utility to be established for various patient groups.

    Patients on the intensive care or high dependency units who have had recent major vascular surgery, emergency bowel surgery, trauma or severe infection will be eligible for this study. Subjects with previously diagnosed acute kidney dysfunction or who are on dialysis or have a kidney transplant will not be eligible for recruitment.

    Participants will have paired 12 hourly samples for serum and urine and subjects will be followed for 72 hours or until the development of AKI, whichever is sooner. Urine samples will be analysed for levels of the two aforementioned biomarkers (TIMP-2 and IGF-BP7). The ability of these biomarkers to predict development of AKI will be compared to the current best available diagnostic tests for AKI: serum creatinine and urine output.

    This study is funded by the Imperial Healthcare NHS Trust (research nurse support). The test kits have been donated by industry (Astute Medical, Inc., USA).

  • REC name

    London - Bromley Research Ethics Committee

  • REC reference

    16/LO/1479

  • Date of REC Opinion

    23 Aug 2016

  • REC opinion

    Favourable Opinion